| For: | Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016; 22(46): 10254-10259 [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i46/10254.htm |
| Number | Citing Articles |
| 1 |
D. Brock Hewitt, Zachary J. Brown, Timothy M Pawlik. Surgical management of intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy 2022; 22(1) doi: 10.1080/14737140.2022.1999809
|
| 2 |
Jian Wang, Qinhong Zheng, Jianxin Chen. The efficacy of olaparib as salvage therapy in an advanced intrahepatic cholangiocarcinoma patient harboring somatic BRCA1 and PALB2 pathogenic variants: a case report and literature review. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1558677
|
| 3 |
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. Medicines 2020; 7(9) doi: 10.3390/medicines7090054
|
| 4 |
Jing-Xiao Yang, Zi-Yao Jia, Fa-Tao Liu, Wen-Guang Wu, Xue-Chuan Li, Lu Zou, Huai-Feng Li, Fei Zhang, Run-Fa Bao, Shu-You Peng, Wan Yee Lau, Yun Liu, Mao-Lan Li, Ying-Bin Liu. Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1078388
|
| 5 |
Öykü Gönül Geyik, Giulia Anichini, Engin Ulukaya, Fabio Marra, Chiara Raggi. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022; 11(9) doi: 10.3390/cells11091463
|
| 6 |
Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.933943
|
| 7 |
Valentina Gárate-Calderón, Rajiv Kumar, Katherine Marcelain, Linda Zollner, Felix Boekstegers, Olga Barajas, Denisse Loader, María Teresa Rivera, Erik Morales, Gonzalo de Toro, Christian Caglevic, Tatsuhiro Shibata, Justo Lorenzo Bermejo. Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis. eBioMedicine 2026; 128 doi: 10.1016/j.ebiom.2026.106305
|
| 8 |
Ahmad Al-Taee, Ammara Gill, Suzanne Mahon, Jinping Lai, Bassel Jallad. Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. Journal of Gastrointestinal Cancer 2019; 50(1) doi: 10.1007/s12029-017-9995-9
|
| 9 |
Jorge Adeva, Bruno Sangro, Massimiliano Salati, Julien Edeline, Adelaida La Casta, Alessandro Bittoni, Rossana Berardi, Jordi Bruix, Juan W Valle. Medical treatment for cholangiocarcinoma. Liver International 2019; 39(S1) doi: 10.1111/liv.14100
|
| 10 |
Xin Yu Li, Jia Qi Chen, Adilai Aisa, Yu Wei Ding, Ding Zhang, Ying Yuan. Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives. Journal of Digestive Diseases 2023; 24(2) doi: 10.1111/1751-2980.13168
|
| 11 |
Bhausaheb Bagal, Rohit Kumar, Tarang Gaur, Vikas Talreja, Avinash Bonda, Nikhil Patkar, Dhanlaxmi Shetty, Pradnya Kowtal, P. G. Subramanian, Sudeep Gupta, Rajiv Sarin, Syed K. Hasan. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. Medical Oncology 2020; 37(5) doi: 10.1007/s12032-020-01371-z
|
| 12 |
Ryosuke Okamura, Razelle Kurzrock, Robert J. Mallory, Paul T. Fanta, Adam M. Burgoyne, Bryan M. Clary, Shumei Kato, Jason K. Sicklick. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. International Journal of Cancer 2021; 148(3) doi: 10.1002/ijc.33230
|
| 13 |
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers 2021; 13(22) doi: 10.3390/cancers13225671
|
| 14 |
Xiaofen Li, Limin Gao, Meng Qiu, Dan Cao. Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. OncoTargets and Therapy 2021; doi: 10.2147/OTT.S303594
|
| 15 |
Mao Li, Yu Mou, Shengzhong Hou, Dan Cao, Ang Li. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib. Medicine 2018; 97(45) doi: 10.1097/MD.0000000000013113
|
| 16 |
|
| 17 |
Zachary J. Brown, Daniel B. Hewitt, Timothy M. Pawlik. Gallbladder Cancer. 2023; doi: 10.1007/978-981-19-6442-8_4
|
| 18 |
Yuan Gao, Junchi Liu, Xiang Yao, Letian Gong, Shubin Luo, Chaoxian Zhao, Shaofeng Pu, Ganglong Gao. DDX11 interacts with PARP1 to facilitate PARylation, thereby promoting gallbladder cancer progression and conferring gemcitabine resistance. Acta Biochimica et Biophysica Sinica 2026; 58(5) doi: 10.3724/abbs.2025155
|
| 19 |
James M. Bogenberger, Thomas T. DeLeon, Mansi Arora, Daniel H. Ahn, Mitesh J. Borad. Emerging role of precision medicine in biliary tract cancers. npj Precision Oncology 2018; 2(1) doi: 10.1038/s41698-018-0064-z
|
| 20 |
Vladimir Bezrookove, John M. Patino, Mehdi Nosrati, Pierre-Yves Desprez, Sean McAllister, Liliana Soroceanu, Ari Baron, Robert Osorio, Mohammed Kashani-Sabet, Altaf A. Dar. Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress. Cancers 2021; 13(17) doi: 10.3390/cancers13174405
|
| 21 |
Margherita Rimini, Teresa Macarulla, Valentina Burgio, Sara Lonardi, Monica Niger, Mario Scartozzi, Ilario G. Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Floriana Nappo, Federico Nichetti, Eleonora Lai, Martina Valgiusti, Alessandro Cappetta, Carles Fabregat-Franco, Matteo Fassan, Filippo De Braud, Marco Puzzoni, Giovanni L. Frassineti, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer 2022; 171 doi: 10.1016/j.ejca.2022.05.004
|
| 22 |
Rutika Mehta, Anthony C Wood, James Yu, Richard Kim. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opinion on Investigational Drugs 2021; 30(4) doi: 10.1080/13543784.2021.1898586
|
| 23 |
Tetiana Glushko, James Costello, Ranjit Chima, Melissa McGettigan, Richard Kim, Daniel Jeong, Aliya Qayyum. Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection. European Journal of Radiology 2025; 187 doi: 10.1016/j.ejrad.2025.112056
|